Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.
Also called NCT07023016
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 515 participants
- Registry
-
NCT07023016
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT07023016. Randomized; no masking; primary purpose treatment. Start 2023-11-01 (actual); primary completion 2025-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
- Acronym
- CAESAR
- Condition
- Acute Decompensated Heart Failure (ADHF)
- Intervention (Drug)
- Sacubitril / Valsartan
- Intervention (Drug)
- Ramipril (ACE-inhibitor (ACE inhibitor))
- Lead sponsor
- National Heart Institute, Egypt
- Collaborator
- Cairo University
Record details
- Record id
cardio:ct-nct07023016- Content hash
4ac578c089b0cda9d4370094ea2614926e370f200fc9212ee070154e3f7f3f4e